Eli Lilly and Company (NYSE:LLY) is Handelsbanken Fonder AB's 6th Largest Position

Handelsbanken Fonder AB reduced its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 765,050 shares of the company's stock after selling 1,975 shares during the quarter. Eli Lilly and Company comprises approximately 2.3% of Handelsbanken Fonder AB's holdings, making the stock its 6th largest holding. Handelsbanken Fonder AB owned 0.08% of Eli Lilly and Company worth $590,619,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. AMF Tjanstepension AB grew its position in Eli Lilly and Company by 113.7% in the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company's stock worth $293,964,000 after acquiring an additional 176,552 shares in the last quarter. Values Added Financial LLC boosted its holdings in shares of Eli Lilly and Company by 4.9% in the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company's stock worth $324,000 after purchasing an additional 17 shares during the period. GAM Holding AG increased its position in shares of Eli Lilly and Company by 55.3% during the 3rd quarter. GAM Holding AG now owns 29,978 shares of the company's stock valued at $26,559,000 after purchasing an additional 10,677 shares during the last quarter. Liberty Capital Management Inc. raised its holdings in Eli Lilly and Company by 5.7% during the 3rd quarter. Liberty Capital Management Inc. now owns 2,150 shares of the company's stock valued at $1,905,000 after buying an additional 115 shares during the period. Finally, Global X Japan Co. Ltd. lifted its position in Eli Lilly and Company by 10.6% in the third quarter. Global X Japan Co. Ltd. now owns 2,614 shares of the company's stock worth $2,316,000 after buying an additional 251 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.1 %

NYSE LLY traded up $1.00 during trading on Friday, reaching $874.12. 3,937,537 shares of the company's stock traded hands, compared to its average volume of 3,765,032. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market cap of $829.82 billion, a price-to-earnings ratio of 74.65, a price-to-earnings-growth ratio of 1.39 and a beta of 0.42. The company's 50 day simple moving average is $799.63 and its two-hundred day simple moving average is $846.07.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company's payout ratio is presently 51.24%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LLY shares. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Wells Fargo & Company cut their price target on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating on the stock in a report on Tuesday, January 28th. Bank of America reissued a "buy" rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Wolfe Research initiated coverage on Eli Lilly and Company in a research report on Friday, November 15th. They set an "outperform" rating and a $1,000.00 target price for the company. Finally, Barclays reduced their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a report on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.